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Intracellular signals are required to activate the leukocyte-specific adhesion receptor 
lymphocyte function-associated molecule-1 (LFA-1; CDlla/CD18) to bind its ligand, 
intracellular adhesion molecule-1 (ICAM-1). In this study, we investigated the role of the 
cytoskeleton in LFA-1 activation and demonstrate that filamentous actin (F-actin) can 
both enhance and inhibit LFA-1-mediated adhesion, depending on the distribution of 
LFA-1 on the cell surface. We observed that LFA-1 is already clustered on the cell surface 
of interleukin-2/phytohemagglutinin-activated lymphocytes. These cells bind strongly 
ICAM-1 and disruption of the actin cytoskeleton inhibits adhesion. In contrast to inter- 
leukin-2/phytohemagglutinin-activated peripheral blood lymphocytes, resting lympho­
cytes, which display a homogenous cell surface distribution of LFA-1, respond poorly to 
intracellular signals to bind ICAM-1, unless the actin cytoskeleton is disrupted. On 
resting peripheral blood lymphocytes, uncoupling of LFA-1 from the actin cytoskeleton 
induces clustering of LFA-1 and this, along with induction of a high-affinity form of 
LFA-1, via "inside-out" signaling, results in enhanced binding to ICAM-1, which is 
dependent on intact intermediate filaments, microtubules, and metabolic energy. We 
hypothesize that linkage of LFA-1 to cytoskeletal elements prevents movement of LFA-1 
over the cell surface, thus inhibiting clustering and strong ligand binding. Release from 
these cytoskeletal elements allows lateral movement and activation of LFA-1, resulting in 
ligand binding and "outside-in" signaling, that subsequently stimulates actin polymer­
ization and stabilizes cell adhesion.
INTRODUCTION
The lymphocyte function-associated molecule-1 
(LFA-1)1 is an adhesion receptor that belongs to the 
family of integrins (CD11/CD18). It consists of an 
a-chain and a ß-chain which are noncovalently linked 
(Kurzinger et ál., 1981). LFA-1 is a leukocyte-specific 
integrin expressed on the cell surface of most leuko­
cytes and coordinates distinct adhesive and signaling 
interaction in the immune system such as T cell-me- 
diated killing, T helper cell and B cell responses, nat­
ural killer cell activity, monocyte-mediated antibody-
* Corresponding author.
1 Abbreviations used: F-actin, filamentous actin, CLSM, confocal 
laser scanning microscopy.
dependent cytotoxicity, and leukocyte adhesion to 
endothelial cells (Springer, 1990; Martz, 1987). These 
highly dynamic interactions are accomplished by in- 
teraction of LFA-1 with intercellular adhesion mole­
cule- (ICAM) 1 (Marlin and Springer, 1987), ICAM-2 
(Staunton et ah, 1989) and ICAM-3 (de Fougerolles and 
Springer, 1992; Fawcett et ah, 1992; Vazeux et a l,  1992; 
de Fougerolles et al., 1993).
LFA-1 expressed by leukocytes is generally not 
functional and must be activated to bind its ligand. 
Triggering of the T cell receptor/CD3 complex (TCR/ 
CD3) or stimulation of leukocytes with phorbol 12- 
myristate 13-acetate (PMA) induces intracellular sig­
nals that activate LFA-1 to bind to its ligand (often 
referred as "inside-out" signaling; Martz, 1987; Dustin 
and Springer, 1989; van Kooyk et ah, 1989; Hynes,
© 1997 by The American Society for Cell Biology 341
1992). As shown for PMA, these intracellular signals 
result in LFA-1 adhesion receptors that have a 200-fold 
higher affinity for binding of ICAM-1 than of the non­
activated receptors (Lollo et al., 1993). Consistent with 
this observation, PMA has been shown to increase the 
diffusion rate of LFA-1, according to the lack of cy­
toskeletal constraints on LFA-1 (Kucik et al, 1996), 
suggesting that PMA activation causes a temporary 
dislodgment of LFA-1 from the cytoskeleton and 
thereby induces an active conformation (high-affinity 
state) of LFA-1. We previously demonstrated that 
LFA-1 can only significantly bind to ICAM-1 when it 
is expressed in clusters at the cell surface (van Kooyk 
et al, 1994). Clustering of integrin molecules is thought 
to enhance the avidity of integrin-ligand interaction 
(Figdor et aL, 1990; van Kooyk et al, 1994). It has 
recently been suggested for <*IIbß3 that ligand binding 
can induce clustering of integrins (Fox et al, 1996). We 
have demonstrated that a unique antibody NKI-L16, 
which recognizes a C a2*-dependent epitope on 
LFA-1, is only expressed by clustered LFA-1, and can 
therefore report the distribution of LFA-1 at the cell 
surface (Keizer et a l ,  1988; van Kooyk et al, 1994). 
LFA-1-mediated adhesion to ICAM-1 can thus be reg­
ulated both by changes in avidity (clustering) and 
affinity (active conformation) of LFA-1 (Lollo et al, 
1993; van Kooyk et al, 1994).
Several antibodies have been described that bind the 
extracellular part of the a- or ß-chain of LFA-1 and are 
capable of inducing an active conformation of LFA-1, 
resulting in increased ligand binding (Keizer et al, 
1988; Robinson et al., 1992; Andrew et al, 1993; Landis 
et al, 1993). It is believed that these anti-LFA-l-acti- 
vating mAbs mimic ligand binding and stimulate 
post-ügand-binding signaling (outside-in signaling). 
Outside-in signaling generates different intracellular 
signals, including phosphorylation of distinct tyrosine 
kinases and other proteins (Kanner et al., 1993; Arroyo 
et al, 1994).
Previous experiments have demonstrated that inte­
grins can associate with cytoskeletal components (a- 
actinin, talin) upon activation (Burn et al, 1988; 
Pavalko and LaRoche, 1993). Inhibitors such as cy- 
tochalasin B and D have been used to inhibit ß2- anc* 
ß ,-mediated adhesion to their ligands (Rothlein and 
Springer, 1986; Haverstick et al, 1992; Pyszniak et al, 
1994). In contrast, it has recently been reported that 
cytochalasins can also induce ß2-mediated function 
(Ross et al, 1992; Elemer and Edgington, 1994; Kucik et 
al, 1996), whereas others showed no effect from these 
inhibitors (Diamond and Springer, 1994; Pyszniak et 
al,  1994). Peter et a l  (1995) showed that the ß2 cyto­
plasmic domain was involved in the localization of 
integrins to focal adhesions and in the organization of 
the actin cytoskeleton into stress fibers (Peter and 
O'Toole, 1995). Truncation of the cytoplasmic domain 
of the ß2 subunit eliminates LFA-1 binding to ICAM-1,
M. Lub et a l
indicating that the cytoplasmic domain of ß2 controls 
adhesiveness (Hibbs et al, 1991a,b). It has been sug­
gested that the reduced adhesiveness of LFA-1 (by 
deletion of the TTT motif in the cytoplasmic domain of 
ß2) is due to the altered association/organization of 
the cytoskeleton rather than a change in the affinity of 
LFA-1 (Peter and O'Toole, 1995). Since the importance 
of the distribution (clustered/dispersed) of LFA-1 at 
the cell surface and its attachment to the cytoskeleton 
became apparent only recently (van Kooyk et al., 1994; 
Lub et al, 1995), we investigated the role of the cy­
toskeleton in the activation of LFA-1 when expressed 
in leukocytes and nonleukocytes. Therefore, we inves­
tigated the distribution and the adhesive capacity of 
LFA-1 on different cell types in the presence or ab­
sence of affinity modulators of LFA-1 (PMA) and cy­
toskeletal inhibitors. Here, we demonstrate that dis­
ruption of the actin cytoskeleton can inhibit or induce 
LFA-l-mediated adhesion to ICAM-1, depending on 
the surface distribution of LFA-1 (clustered /  dis­
persed), but independent of the cell type (leukocytes 
versus nonleukocytes).
MATERIALS AND METHODS 
mAbs and Chemicals
The mAbs SPV-L7 (IgGl), NKÍ-L15 (rgG2a), and NKI-L16 (IgG2a) 
reactive with the a-chain of human LFA-1  (CDlla) were raised as 
described previously (Keizer et al, 1985, 1988). The nonblocking 
mAb TS2/4 (IgGl) reactive with the a-chain of human LFA-1 was 
kindly provided by Dr. E. Martz (Sanchez-Madrid et al, 1982). The 
blocking mAb 60.3 against the /^-chain was kindly provided by Dr. 
Harlan (Beatty et ai., 1983), and the anti-ßj mAb KIM185 (IgGl) was 
used to activate LFA-1 (Andrew et al, 1993). Other reagents used 
were PMA (50 nM, Calbiochem, La Jolla, CA), deoxyglucose (50 
mM, Sigma Chemical Co., St. Louis, MO), and sodiumazide (10 mM, 
Merck, Hohenbrunn, Germany) to deprive the cell from energy, 
acrylamide (4 mM, Bio-Rad Laboratories, Hercules, CA) to block 
intermediate filaments, and nocodazole (10 /xg/ml, Sigma Chemical 
Co.) to block microtubules.
Cells and Cell Lines
A homogenous population of highly purified resting T lymphocytes 
was isolated from buffy coats of healthy donors by centrifugal 
élutriation, as described previously (Figdor et al, 1981). Activated T 
lymphocytes were prepared by culturing these cells with recombi­
nant interleukin- (IL) 2  (400 U/ml, Cetus Corp., Emeryville, CA) 
and phytohemagglutinin (PHA, 0.2 jxg/ml, Murex Diagnostics, 
Dartford, England) in Iscove's medium (Life Technologies, Paisley, 
Scotland) supplemented with 5% fetal calf serum (BioWhittaker, 
Verviers, Belgium) and 1 % antibiotics/antimycotics (Life Technol­
ogies) for 6  days.
L-LFA-1 and BLM-LFA-1 cells were obtained by transfection of 
the complete cDNA of a L (in pCDM8 ) and ß2 (in pRC-CMV con­
taining a neomycin resistance gene, Invitrogen Corporation, San 
Diego, CA) into mouse fibroblast L cells and human melanoma cells 
(BLM; Katano et al., 1984) by Ca2P04 precipitation (calcium phos­
phate transfection system, Life Technologies). After 24 h, the cells 
were maintained in Iscove's medium containing 5% fetal calf serum, 
1 % antibiotics/antimycotics, and the neomycin analogue, genetidn 
(2  mg/ml, Life Technologies). The different transfectants were 
sorted three times to obtain a homogenous population of cells
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expressing high levels of LFA-1. Positive cells were stained directly 
with fluorescein isothiocyanate (FITC)-labeled TS2/4 mAb. Cells 
were sorted using the Coulter Epics Elite (Coulter, Hialeah, FL). For 
establishment of stable L16hl and LI6 10 L-LFA-1  transfectants, L 
cells, transfected with LFA-1 , were incubated (30 min, 4 °C) in phos- 
phate-buffered saline containing 0.5% bovine serum albumin (BSA, 
Boehringer Mannheim, Mannheim, Germany) and 1% antibiotics/ 
antimycotics, with mAb NKI-L16 (10 /xg/ml), followed by incuba­
tion with FITC-labeled goat (Fab' ) 2 anti-mouse IgG mAb (Zymed 
Laboratories, San Francisco, CA) for 30 min at 4°C. Cells were 
positively and negatively selected on expression of the L16 epitope 
by sorting using the Coulter Epics Elite. To obtain a homogenous 
population of L16to- and L16hi-expressing L-LFA-1  cells, the sorting 
procedure was repeated three times.
Immunofluorescence Analysis
Cells were incubated (30 min, 4°C) in phosphate-buffered saline 
containing 0.5% wt/vol BSA and 0.01% sodiumazide, with appro­
priate dilutions of the different mAb, followed by incubation with 
FITC-labeled goat (Fab' ) 2 anti-mouse IgG mAb for 30 min at 4°C. 
The relative fluorescence intensity was measured by FACScan anal­
ysis (Becton Dickinson, Oxnard, CA).
Cell Adhesion Assays
Binding of LFA-1 -positive cells to ICAM-1 was performed using 
ICAM-1  fusion proteins consisting of the five domains of ICAM-1 
fused to a human IgGl Fc fragment (ÏCAM-lFc). Culture superna­
tant of mouse fibroblast cells (L-cells) transfected with pICAM-lFc 
cDNA (Fawcett et aL, 1992) was tested for the presence of ICAM-1 Fc 
in an IgG-specific enzyme-linked immunosorbent assay. To coat 
ICAM-1 Fc, 50 ill of goat anti-human Fc-specific F(ab' ) 2 (4 /ig/ml, 
Jackson ImmunoResearch Laboratories, Westgrove, PA) were pre­
coated on 96-wells flat-bottomed plates (MaxiSorp, Nunc, Roskilde, 
Denmark) for 1 h at 37°C. Subsequently, wells were blocked by 1 % 
BSA in TSM (20 mM Tris-HCl, pH 8,150 mM NaCl, 1 mM CaCl2, 2 
mM MgCl2) for 30 min at 37°C. Culture supernatant of ICAM-lFc 
(approximately 40 n e /ml) was coated for 1 h at 37°C. After labeling 
of the cells with Na2 C r04 (Amersham International, Buckingham­
shire, England) for 1 h at 37°C, they were preincubated with cy- 
tochalasin D (5 fig/ml) in the presence or absence of either deoxy- 
glucose (50 mM) and sodiumazide (10 mM) or acrylamide (4 mM) 
and nocodazole (10 ¿tg/ml) for 30 min at 37°C. Radiolabeled cells 
were preincubated for 1 0  min at room tempera hare with different 
stimuli and/or blocking mAbs. Cells were allowed to adhere for 30 
to 40 min at 37°C. Unbound cells were removed by washing with 
TSM supplemented with 0.5% wt/vol BSA. The adherent cells were 
lysed with 1 0 0  /til of 2 % Triton X-100, and radioactivity was quan­
tified in a gamma counter. Results are expressed as the mean 
percentage of cells binding from triplicate wells. Values are depicted 
as LFA-1-specific adhesion: Percentage of cells binding -  percent­
age of cells binding in the presence of an integrin blocking mAb 
(NKI-L15,10 /xg/ml).
Confocal Microscopy
Adherent cells were grown overnight (adherent cells: BLM and L 
cell transfectants) on glass slides and nonadherent cells [resting 
peripheral blood lymphocytes (PBLs) and activated PBLsl were 
immobilized on glass slides precoated with Celltak adhesive (Col­
laborative Biomedical Products, Bedford, MA). Cells were pre­
treated with cytochalasin D (5 fig/ml; 10 min at 3 7 °C) and activated 
with PMA (50 nM) for 20 min at 37°C in the presence of cytochalasin
D, followed by fixation with 0.5% paraformaldehyde. Fixed cells 
were stained with the mAb TS2/4 (10 /xg/ml) for 30 min at 37°C, 
followed by incubation with FITC-labeled goat (Fab' ) 2 anti-mouse 
IgG mAb for 30 min at room temperature. Cell surface distribution 
of integrins was determined by confocal laser scanning microscopy
(CLSM) at 488 nm with a krypton/argon laser (Bio-Rad). In all 
experiments, the same instrument settings of the CLSM were used.
RESULTS
Expression o f LFA-1 by L Cell Fibroblasts and BLM  
Melanoma Cells
To compare the function of LFA-1 in leukocytes with 
that in nonleukocytes, we generated transfectants in 
which both the a and ß subunit of LFA-1 were trans­
fected. We expressed LFA-1 in murine fibroblast cells 
(L cells) and human melanoma cells (BLM). Expres­
sion level of the a-chain of LFA-1 was similar to that 
on resting and IL-2/PHA-activated PBLs (Figure 1), 
Expression of the ß-chain of LFA-1 was higher on 
activated PBLs compared with resting PBLs, which is 
caused by expression of Mac-1 and pl50.95, other 
members of the ß2 integrin subfamily, on activated 
PBLs (Figure 1).
Since multimerization or clustering of LFA-1 (high 
avidity) facilitates binding to ICAM-1, we investigated 
expression of the LI 6 epitope, which reports the clus­
tered status of LFA-1 on the cell surface of hematopoi­
etic cells (van Kooyk et at., 1994). Staining LFA-1 with 
mAb NKI-L16 reveals distinct expression patterns of 
this epitope, depending on the cell type. Both BLM- 
LFA-1 and L-LFA-1 transfectants show an L16 expres­
sion, which equals the expression of LFA-1 obtained 
with a regular mAb SPV-L7 (NKI-L16:SPV-L7 peak 
channel ratio = 1, ranging from 0.9 to 1.2) and is 
comparable to activated PBLs. In contrast, LFA-1 on 
resting PBLs expresses significantly less of the LI 6 
epitope (NKI-L16:SPV-L7 peak channel ratio = 0.2, 
ranging from 0,1 to 0.3). This indicates that LFA-1, on 
BLM, L cell transfectants, and activated PBLs, is con- 
stitutively expressed in clusters on the cell surface.
To prove that L16 expression on these transfectants 
indeed correlates with LFA-1 clustering as it does on 
leukocytes, we analyzed the surface distribution of 
LFA-1 on the L-LFA-1 and BLM-LFA-1 transfectants 
by confocal microscopy and compared it with the 
distribution of LFA-1 on resting and IL-2/PHA-acti- 
vated T cells (Figure 2). The two LFA-1 transfectants 
that express high levels of the LI 6 epitope (Figure 2, A, 
L-LFA-1; and B, BLM-LFA-1) show a clustered distri­
bution of LFA-1 on the cell surface similar to IL-2/ 
PHA-activated PBLs (Figure 2C). In contrast, resting 
PBLs show a dispersed distribution of LFA-1 (Figure 
2D), which corresponds with the low L16 expression 
on these cells. In conclusion, also in nonhematopoietic 
cells, expression of the L16 epitope correlates with a 
clustered distribution of LFA-1.
Clustering of LFA-1 Facilitates ICAM-1 Binding
Since the various LFA-1 transfectants exhibited major 
differences in LFA-1 distribution, we investigated the
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Figure 1. Expression of LFA-1 and the LFA-1 ac­
tivation epitope (LI6) on distinct cells. L-LFA-1, 
BLM-LFA-1, and resting and ÍL-2/PHA-activated 
PBLs were stained with either isotype-matched 
control antibodies or specific antibodies directed 
against the a subunit of LFA-1 (SPV-L7) an d  (NKI- 
L16) or the ß-chain of LFA-1 (60.3) and GAM- 
(Fab')2~FITC second antibodies. NKI-L16:SPV-L7 
ratio is mentioned in the NKI-L16 histogram. One 
of five experiments is shown.
intrinsic activation state of the receptor by measuring 
LFA-1-media ted adhesion to ICAM-1 without the ad­
dition of any activating stimuli. The results in Figure 3 
demonstrate that BLM-LFA-1-, L-LFA-1-, and IL-2/ 
PHA-activated PBLs spontaneously bind to ICAM-1. 
In contrast, resting PBLs that show a dispersed LFA-1 
distribution hardly bind to ICAM-1 in the absence of
stimuli (Figure 3). The binding to ICAM-1 is LFA-1 
specific and could not be attributed to Mac-1 or 
p i50.95 expression, since the depicted specific binding 
was determined in the presence of a blocking anti- 
LFA-1 a mAb. The difference in the spontaneous ad­
hesion of these cells to ICAM-1 is not due to distinct 
levels of LFA-1 expression, since all cells have similar 
levels of LFA-1 expression (SPV-L7), but only differ in
Figure 2. Surface distribution of LFA-1 expressed as determined 
by CLSM using a FITC-labeled anti-LFA-1 mAb TS2/4. LFA-1 is 
localized in large clusters on L-LFA-1 (A), BLM-LFA-1 (B), and on 
IL-2/PHA-activated PBLs (C), whereas it is dispersed on resting 
PBLs (D). The instrum ent settings of the CLSM were the same for 
the distinct photographs.
»¿tul
na
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I
to
L-LFA-1 BLM-LFA-1
non-leukocytes
resting PBL activated PBL
-aflj-----...........
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Figure 3. Spontaneous LFA-1-mediated adhesion to ICAM-1. L- 
LFA-1 , BLM-LFA-1, resting PBLs, and IL-2/PHA-actìvated PBLs 
were allowed to adhere to chimeric ICAM-lFc-coated wells for 30 
min at 37°C. Depicted is the mean percentage of LFA-1-specific 
adhesion to ICAM-1 of triplicate wells. Specific adhesion is the 
percentage of cells binding -  the percentage of cells b ind ing  in the 
presence of an LFA-1 blocking mAb (NKI-L15). Adhesion which 
could not be blocked by NKI-L15 was always less than 5% on 
activated PBLs. One representative experiment of five is show n.
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expression of the LI6 epitope (Figure 1). These data 
indicate that clustering of LFA-1 on the cell surface 
induces LFA-1/ICAM-1 binding (van Kooyk et al, 
1994).
Since binding to ICAM-1, which alters the affinity 
state of LFA-1, can also be enhanced upon activation 
of cells with PMA (Lollo et aL, 1993), we activate the 
cells with PMA and the activating anti-LFA-1 ß mAb 
KIM185 which both induce an active conformation 
(high-affinity state) of LFA-1. The results in Figure 
4A show that binding of resting PBLs to ICAM-1 
indeed requires additional stimuli, like KIM185 or 
PMA. In contrast, adhesion of IL-2/PHA-activated 
PBLs, BLM-LFA-1, and L-LFA-1 to ICAM-1, which 
bind already spontaneously to ICAM-1 (Figure 3), 
can be further increased by PMA or the activating 
mAb KIM 185 (Figure 4, B-D). However, PMA is 
significantly less effective in inducing LFA-1-medi­
ated adhesion to ICAM-1 of resting PBLs (Figure 
4A) when compared with IL-2/PHA-activated PBLs 
(Figure 4B), which is in line with previous findings 
(van Kooyk et ai., 1993,1994). Thus, when LFA-1 is 
expressed on either hematopoietic or nonhemato- 
poietic cells, adhesion to ICAM-1 can be induced by 
alteration in avidity (clustering) or affinity (induced 
by PMA or KIM185), whereas both avidity and af­
finity alteration cooperate to induce maximal adhe­
sion.
A
Control
PMA
K1M185
C
Control
PMA
KIM 185
LFA-1 mediated adhesion to I CAM-1 (%)
Figure 4. Induction of LFA-1-mediated adhesion to ICAM-1 of 
adherent transfectants and leukocytes by different LFA-1-activating 
stimuli. Resting PBL cells (A), IL-2 /PHA-activated PBLs (B), BLM- 
LFA-1 (C), and L-LFA-1  (D) were preincubated in medium (control), 
PMA (50 nM), or the activating antibody KIM185 (5 ptg/ml). De­
picted is the mean percentage of LFA-1-specific binding to ICAM-1 
of three independent wells. Specific adhesion is the percentage of 
cells binding -  the percentage of cells binding in the presence of an 
LFA-1 blocking mAb (NKI-L15). Adhesion which could not be 
blocked by NKI-L15 was always less than 5% on IL-2/PHA-acti­
vated PBLs. Data are representative of three experiments.
Dual Role of Filamentous Actin (F-Actin) in 
Regulating LFA-1 Function
The importance of the association of cytoskeletal com­
ponents (a-actinin and talin) with the /32-chain has 
been reported previously (Burn et aL, 1988; Pavalko 
and LaRoche, 1993). However, it is not known 
whether association with the cytoskeleton is impor­
tant in modulating the affinity, the distribution of 
LFA-1, or both. We therefore investigated the role of 
the actin cytoskeleton in LFA-1-mediated adhesion to 
ICAM-1 by different cell types, which either show a 
dispersed (resting PBLs) or a clustered LFA-1 distri­
bution (IL-2/PHA-activated PBLs) on the cell surface.
Interestingly, when actin polymerization is inhibited 
in resting or in IL-2/PHA-activated T cells, clear dif­
ferences are observed. Treatment of resting PBLs (dis­
persed LFA-1 distribution) with cytochalasin D or 
PMA increases adhesion of LFA-1 to ICAM-1. How­
ever, cytochalasin D treatment followed by activation 
of the cells with PMA results in more than a twofold 
increase in LFA-1-mediated adhesion to ICAM-1 com­
pared with untreated, PMA-stimulated cells (Figure 
5A), suggesting that both uncoupling of LFA-1 from 
the cytoskeleton and induction of an active conforma­
tion are necessary to achieve strong adhesion. In con­
trast, treatment of IL-2/PHA-activated PBLs (clus­
tered LFA-1 distribution) with cytochalasin D results 
in a decreased LFA-1-mediated adhesion to ICAM-1, 
with or without the activation of LFA-1 with PMA 
(Figure 5B).
Since on K562 cells transfected with a ß2 cytoplasmic 
deletion mutant of LFA-1, LFA-1 is localized in large 
clusters and cytochalasin D uncouples actin from in­
tegrin molecules, the enhanced motility of LFA-1 at 
the cell surface may allow cluster formation that re­
sults in an increased adhesion to ICAM-1, we hypoth­
esize that the cytoskeleton affects the distribution of
resting PBL activated PBL
Control
PMA
B
)
10 20 30 0 20 40
LFA-1 mediated adhesion to ICAM>1(%)
60 80
Figure 5. Role of F-actin in regulating LFA-1-media ted adhesion. 
LFA-1-mediated adhesion to ICAM-1 of cytochalasin D-treated (■) 
or untreated cells (D). PBLs (A) and IL-2 /PHA-activated PBLs (B) 
were first treated with cytochalasin D (5 /Ag/ml, 30 min at 37°C) or 
untreated as a control, followed by preincubation with PMA (50 
nM). The mean percentage of LFA-1-specific adhesion of triplicate 
wells is shown. Specific adhesion is the percentage of cells bind­
ing — the percentage of cells binding in the presence of a LFA-1 
blocking mAb (NKI-L15). Adhesion which could not be blocked by 
NKI-L15 was always less than 5% on IL-2/PHA-activated PBLs. 
One representative experiment of three is shown.
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LFA-1. To test this hypothesis, resting PBLs were pre­
treated with cytochalasin D and stained with an anti- 
LFA-la mAb (Figure 6). Figure 6A shows the diffuse 
LFA-1 cell surface distribution on untreated resting 
PBLs, whereas Figure 6, C and D, demonstrate that 
cytochalasin D treatment of these cells results in a 
clustered LFA-1 distribution more similar to the clus­
tered LFA-1 distribution observed on IL-2/PHA-acti­
vated PBLs (Figures 2C and 7A). Together with the 
adhesion data, this suggests that cytochalasin D in­
duces LFA-1 /ICAM-1 adhesion by increasing the 
avidity (clustering) of LFA-1 on resting PBLs. PMA 
activation itself has no effect on the cell surface distri­
bution of LFA-1 on untreated cells (Figure 6B) or on 
cytochalasin D-treated cells (Figure 6D), indicating 
that PMA alters the affinity rather than the avidity of 
LFA-1. In contrast, treatment of IL-2/PHA-activated 
PBLs with cytochalasin D blocks the adhesion of these 
cells to ICAM-1 (Figure 5B). Cytochalasin D does not 
seem to affect the clustered distribution of LFA-1 on 
the cell surface (Figure 7,C and D), as measured by 
CLSM. However, we cannot exclude that cytochalasin 
D also affects to some extent the distribution of LFA-1 
on IL-2/PHA-activated PBLs, since minor differences 
in preexisting clusters cannot be distinguished by 
CLSM. PMA activation has no effect on the LFA-1 
distribution of IL-2/PHA-activated PBLs (Figure 7, B 
and D), whereas it has been shown to enhance adhe­
sion of these cells to ICAM-1 (Figure 5B). Together
Figure 6. LFA-1 d istribution of cytochalasin D-treated resting 
PBLs shifts toward a clustered distribution of LFA-1. Resting PBLs 
w ere pretreated w ith  cytochalasin D (5 ¿ig/m l, C and D) or as a 
control untreated (A and B) and were either activated w ith  PMA (B 
and D) or nonactivated (A and  C). Ail cells were stained for 30 min 
with the anti-LFA-1 mAb TS2/4 (10 /u,g/ml) and FITC-labeled goat 
(Fab ')2 anti-mouse IgG. Fluorescence distribution was determined 
with CLSM at 488 nm, The instrum ent settings of the CLSM were 
the same for the distinct panels.
with recent findings (Kucik et al., 1996), this suggests
tocha la sin D affects the avidity of LFA-1,
To summarize our findings (Figure 8) on resting 
PBLs, LFA-1 is homogenously distributed and hardly 
binds ICAM-1. Only the combination of PMA, to in­
duce a high-affinity receptor, and cytochalasin D treat­
ment results in a clustered LFA-1 cell surface distri­
bution and strong ICAM-1 binding (30%). On IL-2/ 
PHA-activated PBLs, LFA-1 is already found in macro 
clusters and binds ICAM-1 in the absence of any stim ­
ulus (30%). PMA activation of IL-2/PHA-activated 
PBLs can increase the affinity of LFA-1 for ICAM-1 
binding (67%). Inhibition of the actin polymerization 
in these cells decreases adhesion to ICAM-1 to the 
level of the nonstimulated IL-2/PHA-activated PBLs, 
probably by decreasing the major clustering of LFA-1 
on these cells, which we cannot distinguish with 
CLSM (see DISCUSSION). These data suggest that the 
actin cytoskeleton is involved in two steps of the ac­
tivation process of LFA-1: it maintains LFA-1 in a 
homogenously distributed (low-avidity) state on rest­
ing PBLs, and the actin cytoskeleton maintains LFA-1 
in a high-avidity state (clustered) on activated PBLs.
Dual Role of F-Actin in LFA-1-mediated Adhesion 
Is not Restricted to Leukocytes
To investigate whether the dual role of F-actin in 
regulating LFA-1 function is restricted to leukocytes,
Figure 7. Cytochalasin D does not affect the LFA-1 distribution on 
IL-2/PHA-activated PBLs. IL-2 /PHA-activated PBLs were p re­
treated with cytochalasin D (5 pLg/mì; C and D) or as a control 
untreated (A and B) and were either activated with PMA (B and D) 
or nonactivated (A and C). All cells were stained for 30 min with the 
anti-LFA-1 mAb TS2/4 (10 /mg/ml) and FITC-labeled goat (Fab ') 2 
anti-mouse IgG. Fluorescence distribution was determined by 
CLSM at 488 nm. The same instrument settings of the CLSM were 
used throughout the experiment.
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Figure 8. The d u a l role of F-actin in regulating LFA-1-mediated 
adhesion and its correlation w ith  the distribution of LFA-1 on both 
resting and IL-2/PH A -activated PBLs. This figure integrates the 
adhesion data presented in Figure 5 w ith  the distribution data  
show n in Figures 6 and 7. Cytochalasin D (CD) induces LFA-1 
clustering and ICAM-1 adhesion on resting PBLs, whereas it does 
not affect the LFA-1 distribution, b u t  inhibits the binding to ICAM-l 
of IL-2/PHA-activated PBLs. Adhesion which could not be blocked 
by NKI-L15 was always less than 5% on IL-2/PHA-activated PBLs.
we determined the effect of cytochalasin D on the 
adhesion to ICAM-1 of two distinct L-LFA-1 transfec­
tants. We therefore selected L-LFA-1 cells that have a 
low expression of the LI6 epitope (Figure 9; NKI-L16: 
SPV-L7 peak channel ratio of approximately 0.1) in 
contrast to the normal L-LFA-1 transfectants that ex­
press high levels of the LI 6 epitope (Figure 9; NKI- 
L16:SPV-L7 peak channel ratio of approximately 1). 
The L161d (resting) L-LFA-1 transfectants show in­
creased adhesion to ICAM-1 upon preincubation with 
cytochalasin D and stimulation with PMA (Figure 10), 
whereas the adhesion of L16hi (activated) L-LFA-1 
cells is inhibited under the same conditions (Figure 
10). This indicates that the dual role of F-actin in 
regulating LFA-1 function is independent on the cell 
type on which LFA-1 is expressed.
Intact Intermediate Filaments, Microtubules, and 
Energy Are Essential in LFA-1/ÏCAM-1 Binding of 
Cytochalasin D-treated Cells
To determine whether induction of adhesion by cy­
tochalasin D is an active, energy-dependent process, 
we treated resting LI 6lo-expressing L-LFA-1 cells with 
sodiumazide and deoxyglucose, Our unpublished re­
sults demonstrated that sodiumazide or deoxyglucose 
alone was not effective in blocking the cytochalasin 
D-induced adhesion, whereas a combination of both 
inhibited adhesion, indicating that induction of adhe­
sion caused by cytochalasin D is energy dependent
(Figure 11). To analyze whether other cytoskeletal pro­
teins participate in the cytochalasin D-induced adhe­
sion of L16io L-LFA-1 cells to ICAM-1, we treated the 
cells with acrylamide and nocodazole, disrupting the 
intermediate filaments and microtubules, respectively. 
Neither nocodazole nor acrylamide alone was effec­
tive in inhibiting adhesion, whereas Figure 11 dem on­
strates that the induced adhesion of cytochalasin ID- 
treated cells is inhibited by a combination of 
acrylamide and nocodazole. This indicates that both 
intermediate filaments and microtubules are essential 
to mediate this adhesion to ICAM-1. Our unpublished 
observations demonstrated that disruption of the in­
termediate filaments or microtubules in cells that are 
L16hl did not inhibit LFA-1 mediate adhesion to
ICAM-1.
DISCUSSION
We have demonstrated the following: 1) On resting 
leukocytes, LFA-1 is homogenously distributed, 
whereas on IL-2 /  PHA-activated PBLs LFA-1 is local­
ized in clusters on the cell surface. 2) On cells with a 
clustered LFA-1 phenotype, association of LFA-1 with 
the actin cytoskeleton is essential for strong adhesion 
to ICAM-1. 3) Uncoupling F-actin from LFA-1 (by 
cytochalasin D) induces LFA-1-mediated binding to 
ICAM-1 of cells that have a homogenous LFA-1 sur­
face distribution by facilitating lateral movement of 
LFA-1 into clusters. 4) This cytochalasin D-induced 
adhesion to ICAM-1 is dependent on both intact in­
termediate filaments and microtubules and is energy 
dependent.
On resting PBLs, LFA-1 is homogenously distrib­
uted and hardly binds ICAM-1, In contrast, on IL-2/ 
PHA-activated PBLs and L-LFA-1 and BLM-LFA-1
transfectants, LFA-1 is localized in huge clusters and 
spontaneously binds ICAM-1 (approximately 
20-30%). In addition, adhesion of these cells can be 
increased by PMA or the activating mAb K1M185, 
demonstrating that besides clustering of LFA-1 (avid­
ity), affinity changes in the LFA-1 molecule (active 
conformation) are still required for strong binding to 
ICAM-1. These findings, along with data that integrins 
can associate with cytoskeletal components (a-actinin 
and talin), in particular through the ß-chain (Burn et 
al, 1988; Pavalko and LaRoche, 1993), led us to hy­
pothesize that certain cytoskeletal proteins are essen­
tial to maintain LFA-1 in a high-avidity state on these 
cells. The observation that cytochalasin D, which in­
hibits actin polymerization, blocks the adhesion (in the 
absence of an activator of LFA-1) of the L cell, BLM 
transfectants, and IL-2/PHA-activated PBLs supports 
this hypothesis and demonstrates that this phenome­
non is not leukocyte restricted. In contrast, on resting 
PBLs and L-LFA-1/LI6l0, detachment of the distrib­
uted homogenous LFA-1 from the actin cytoskeleton,
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Figure 9. Expression of the LFA-1 activation 
epitope (LI6 ) on L16hl and L16!o L-LFA-1 transfec­
tants. L16hi and L16lu L-LFA-1 transfectants were 
stained with either iso type-matched control antibod­
ies or specific antibodies directed against the a  sub­
unit of LFA-1 (SPV-L7 and NKI-L16) and GAM- 
(Fab')2-FITC second antibodies. The NKI-L16: 
SPV-L7 ratio of both transfectants is mentioned in 
the histograms. One of five experiments is shown.
by cytochalasin D, may facilitate redistribution of 
LFA-1 into clusters (Figure 6; Lub et al., 1995). Cells 
with this high-avidity form of LFA-1 (clustered) will 
bind better to ICAM-1 than cells on which LFA-1 is 
homogenously distributed, thus explaining the en­
hanced adhesion when these cells are treated with 
cytochalasin D. On IL-2/PHA-activated PBLs, cluster­
ing of LFA-1 may be caused by culturing these cells 
with IL-2 and PH A, since it is possible that IL-2/PH A 
activates LFA-1 to interact with ICAM-1 on the oppo­
site cell, thereby causing cytoskeletal reorganizations 
and clustering of LFA-1 on these cells, as has been 
suggested recently for the aIIbß3 integrin (Fox et aL, 
1996). The observation that PMA is required demon­
strates that clustering of LFA-1 in itself is essential but 
not sufficient to stimulate strong adhesion. Both a 
high-avidity (clustering) and high-affinity state (active 
conformation) of LFA-1 cooperate for strong adhesion. 
Our unpublished results demonstrate that in contrast 
to LFA-1, on both resting and IL-2/PHA-activated 
PBLs, ß i integrin-mediated adhesion is always inhib­
ited when actin polymerization is inhibited, indicating 
that ß: and ß2 integrins differ in their coupling to the 
cytoskeleton.
Figure 12 explains the dual role of the actin cy­
toskeleton in the activation of LFA-1 in leukocytes. 
In this model the correlation between adhesion ca­
pacity and cell surface distribution of LFA-1 on 
leukocytes is depicted. When LFA-1 is inactive, as 
on resting PBLs, it has a dispersed distribution and 
actin filaments keep the LFA-1 molecules in a low- 
avidity state (repression). Temporarily uncoupling 
of LFA-1 from the cytoskeleton by PMA is necessary 
to allow conformational changes in the LFA-1 mol­
ecule (Kucik et aL, 1996). Along with lateral move­
ment of the adhesion receptor by cytochalasin D, 
this results in the acquisition of clustered (high- 
avidity) LFA-1 molecules with high ligand-binding 
affinity (Lub et aL, 1995), Recently it has also been 
shown by others that release from cytoskeletal con­
straints is an important early step in activation of 
adhesion, and that the actin cytoskeleton is actively
maintaining LFA-1 in its nonadhesive (low-affinity 
and -avidity) state (Kucik et al., 1996). Furthermore, 
other cytoskeletal proteins (e.g., intermediate fila­
ments and microtubules) are essential for the in­
duced LFA-1-mediated adhesion of cytochalasin D- 
treated cells to ICAM-1. The association of LFA-1 
with these cytoskeletal proteins may either induce 
an active conformation of LFA-1, allow lateral 
movement of LFA-1 on the cell, or a combination of 
both. More evidence comes from K562 cells trans­
fected with a ß 2 cytoplasmic deletion mutant of 
LFA-1. On these transfectants, LFA-1 is localized in 
large clusters, suggesting that uncoupling of the ß2 
from the cytoskeleton indeed facilitates redistribu­
tion of LFA-1 (Lub, van Vliet, Oomen, Pieters, Rob­
inson, and van Kooyk, unpublished data). These 
data suggest that F-actin is important in maintain­
ing LFA-1 in its low-avidity state on resting PBLs 
(Figure 12, 1), whereas it is important to maintain 
LFA-1 in its high-avidity state (clustered) on IL-2/ 
PHA-activated PBLs (Figure 12, 5) and L16hl trans­
fectants. However, we probably cannot distinguish 
the minor difference in LFA-1 clustering on cytocha­
lasin D-treated resting PBLs (clustering stage II, Fig­
ure 12, 3 and 4) and LFA-1 clustering on unstimu­
lated IL-2/PHA-activated PBLs (clustering stage III, 
Figure 12, 5 and 6), since only major differences in 
clustering can be distinguished by CLSM (Figure 12; 
major differences in clustering between stage I and 
II can be observed with CLSM). The transition from 
inactive to active LFA-1 molecules is clearly depen­
dent on intermediate filaments and microtubules. In 
addition, cytochalasin D seems to lower the avidity 
of LFA-1 on IL-2/PHA-activated PBLs, whereas it 
increases the avidity of LFA-1 on resting PBLs, sug­
gesting that the association of LFA-1 with the cy­
toskeleton is different in resting PBLs compared 
with IL-2/PHA-activated PBLs.
The notion that cytochalasins induce rather than 
inhibit adhesion is also supported by several recent 
findings. It has been demonstrated that inhibition of 
actin polymerization by cytochalasins increases in-
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Figure 1 0 . Distinct role of the actin cy­
toskeleton in LFA-1-mediated ICAM-1 
binding of L1610 and L16hi L-LFA-1  
transfectants. L-LFA-1 transfectants that 
show a high LI 6  expression and L- 
LFA-1 cells that exhibit a low L16 ex­
pression were treated with cytochalasin 
D (ffl, 5 Mg/ml, 30 min at 37°C) or un­
treated (□). Depicted is the percentage 
of LFA-1-mediated adhesion to ICAM-1  
of nontreated or cytochalasin D-treated 
cells in triplicate wells. LFA-1-mediated 
adhesion is the percentage of cells bind­
ing -  the percentage of cells binding in 
the presence of an LFA-1 blocking mAb 
(NKI-L15). Data are representative of 
three experiments.
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tegrin motility on endothelial cells (Wang et aL, 
1993). Furthermore, it has been shown (Elemer and 
Edgington, 1994) that inhibition of actin polymer­
ization enhances ligand binding by Mac-1 on mono­
cytic cells and by LFA-1 on B cells (Kucik et aL, 
1996). In addition, inhibition of actin polymerization 
increases the ability of macrophages to form 
pl50.95-dependent C3-opsonized sheep erythrocyte 
(EC3bi) rosettes (Ross et aL, 1992). The opposite 
effects of cytochalasins, e.g., inhibition (Rothlein 
and Springer, 1986; Haverstick et aL, 1992; Pyszniak
Control“
r
• • • •  s
PMA-Y//jfjy//sssss/ssj
LFA-1 mediated adhesion (%)
Figure 11. Cytochalasin D-dependent induction of adhesion of 
L16l° L-LFA-1 cells is dependent on intact intermediate filaments, 
microtubules, and energy. L16‘° L-LFA-1 cells were untreated (□) or 
treated with metabolic inhibitors: deoxyglucose and sodiumazide 
(50 mM and 1 0  mM, respectively, ■), with inhibitors of the inter­
mediate filaments and microtubules, like acrylamide and nocoda­
zole (4 mM and 10 jig/ml, respectively, É), cytochalasin D (5 
jxg/ml, M) alone, along with deoxyglucose and sodiumazide (S), or 
along with acrylamide and nocodazole (H). Subsequently, cells were 
activated with PMA with or without the blocking anti-LFA-1 mAb 
NKI-L15 and allowed to adhere to chimeric ICAM-1 Fc for 30 min at 
37°C. Depicted is the percentage of LFA-1-specific adhesion to 
ICAM-1 of nontreated or treated cells in triplicate wells. Specific 
adhesion is the percentage of cells binding -  the percentage of cells 
binding in the presence of an LFA-1 blocking mAb (NKI-L15). Data 
are representative of three experiments.
et aL, 1994), induction (Ross et aL, 1992; Elemer and 
Edgington, 1994; Kucik et aL, 1996), or no effect 
(Diamond and Springer, 1994; Pyszniak et aL, 1994) 
in integrin-mediated adhesion can be explained by 
the following: 1) The use of the more nonspecific 
actin polymerization inhibitor cytochalasin B in­
stead of the more specific cytochalasin D occurred. 
2) In a large number of the studies, cell aggregation 
assays were used rather than adhesion assays to 
purify ICAM-1. 3) The distribution state of the inte­
grins on the cell surface was never investigated.
We have demonstrated that coupling of LFA-1 to the 
actin cytoskeleton is independent of the cell type (leu­
kocytes compared with nonleukocytes). Furthermore, 
activation of LFA-1 and subsequent ligand binding 
depends both on the distribution and on the affinity 
state of the receptor. F-actin has dual functions: 1) to 
maintain LFA-1 molecules in a clustered form (IL-2/ 
PHA- activated PBLs; LFA-1/LI 6hl) and 2) to act as a 
repressor to hold LFA-1 molecules in an inactive form, 
distributed over the cell surface (resting PBLs; LFA- 
1/L1610). We hypothesize that these LFA-1 molecules 
can only become sensitive to "inside-out" activation 
when they are temporarily dislodged from the cy­
toskeleton. Leukocytes require mechanisms to regu­
late LFA-1 adhesion, since they should be able to 
circulate as nonadherent cells in blood and lymph and 
to migrate as adherent cells throughout the tissues. 
Detachment from and coupling to the actin cytoskel­
eton provides leukocytes with a mechanism to rapidly 
alter both the avidity and affinity of LFA-1 to respond 
to physiological stimuli occurring in vivo.
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Figure 12. Â model that explains the dual role 
of the actin cytoskeleton in the regulation of 
LFA-1-mediated adhesion. Depicted is the cor­
relation between adhesion an d  distribution of 
LFA-1 ori both resting and IL-2/PHA-activated 
PBLs and the role of the actin cytoskeleton in 
these processes. On resting PBLs, monomeric 
LFA-1 receptors are inactive due to connection 
to the actin cytoskeleton (1), LFA-1 adhesion 
can be increased by induction of a high-affinity 
state (active conformation) of LFA-1, through 
conformational changes, by the phorbol ester 
PMA (2). On resting PBLs, uncoupling  of LFA-1 
from the actin cytoskeleton by cytochalasin D 
(CD) induces clustering (high-avidity state) of 
LFA-1 and thereby enhances LFA-1 /ICAM-1 
binding (3). Subsequent PMA stim ulation en­
hances adhesion to ICAM -1 by induction of a 
high-affinity state (active conformation) of 
LFA-1 (4). In contrast, on activated PBLs (5), 
LFA-1 is initially clustered and adhesion can be 
further increased by enhancing the binding af­
finity of LFA-1 by PMA (6). Cytochalasin D 
treatment of IL-2/PHA-activated PBLs p a r­
tially reduces the avidity (clustering) of LFA-1 (3), resulting in a decreased adhesion to ÏCAM-1. Clustering of LFA-1 is depicted in different 
stages (I—III): stage I is no clustering/m icroclustering of LFA-1 and stage III is macroclustering. Minor differences in clustering betw een stages 
H and III cannot be m easured with CLSM. Gray boxes indicate the initial state of LFA-1 on resting (1) and IL-2/PHA-activated PBLs (5) prior 
to PMA or cytochalasin D treatment.
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